TLSI Stock Forecast & Price Target

TriSalus Life Sciences is supported by a differentiated PEDD platform that addresses a clear technical barrier in solid-tumor treatment: high intratumoral pressure that limits drug delivery and increases off-target exposure. Commercially, TriNav is already gaining traction, with 2025 revenue of $45.2M, up 53% year over year, and 2Q26 revenue of $11.4M beating consensus despite a temporary sales-force reset. The outlook is strengthened by expansion catalysts such as TriNav Advance, broader reimbursement, and nelitolimod-enabled upside, while modeled gross margin is expected to improve from 84.6% in FY25 to 85.2% in FY26 and roughly 90% by FY34.

TriSalus Life Sciences is viewed negatively because substantially all revenue depends on TriNav adoption, leaving the business exposed to commercial concentration, limited physician awareness, and competition from cheaper standard microcatheters sold by larger rivals. Regulatory and clinical uncertainty also weigh heavily, as TriNav Advance remains under FDA review and the PEDD evidence base is still largely retrospective, real-world, and single-center, while the bear case excludes GAE and caps total revenue at about $307M in 2034E. Although gross margin remained strong at 86.8% in 2Q26 and list price held at $7,982 per catheter, sales and marketing expense rose 59.4% YoY to $11.4M, underscoring the costly commercialization build-out and the risk of future dilution if the company remains unprofitable.